Top Stories
AI Structural Biology Network members AbbVie, AstraZeneca, Bristol Myers Squibb and J&J are working on a new initiative to support virtual screening and lead optimisation.
The company lined up for an IPO the same day it signed an AI drug discovery deal with AbbVie.
The smart ring maker expects to end fiscal 2026 with about 5.7 million paid members, up 96% from a year earlier.
Iambic’s Enchant v3 will be used by AbbVie across immunology, neuroscience and oncology, marking the AI firm's third large pharma partnership this year after Takeda and Bayer deals.
The AI firm is also continuing to invest in its internal life sciences research, recently opening up a wet lab in California.
Conference News
Rapid Oral presentation will report initial Phase I data for ISM6331 in patients with advanced solid tumorsFDA Fast Track- and Orphan Drug-designated program reflects Insilico’s strategy to advance AI...
Late-breaking study presented at HRX 2026 met primary feasibility endpoint in 100% of patientsMajority of patients had minimal or no AF symptoms at 12 monthsSTAR Apollo™ Mapping System identifies atri...
The 16 mm, 1 g all-in-one CGM updates every 2 minutes and is designed to work with the Nano tubeless insulin pump as part of Medtrum’s compact AID systemMILAN, ITALY, September 22, 2026 /EINPresswire....
NEW YORK--(BUSINESS WIRE)-- Radformation, a leading provider of intelligent automation solutions for radiation oncology, today announced the expanded U.S. Food and Drug Administration (FDA) 510(k) cle...
Data on >1,100 patients presented at the World Conference on Lung Cancer shows Signatera MRD status strongly predicted recurrence-free and overall survival in resected non-small cell lung cancer, with...
